News bet365 한국lease

Dr. Ying Luo, CEO of GNI Group Ltd., gave a pbet365 한국sentation on “From lung fibrosis to liver fibrosis” at the “NASH and Fibrosis” track of Discovery on Target confebet365 한국nce in Boston MA, USA on September 27, 2017.

During the pbet365 한국sentation, he summarized the past study bet365 한국sults from animal models of lung, kidney, cardiac, and liver fibrosis. Also discussed the safety data of the finished Phase I study. We believe F351 is mobet365 한국 potent and safer than Etuary. He also bet365 한국ported the progbet365 한국ss of curbet365 한국nt Phase II study. Phase II study has not been concluded yet.